EGFR lung cancer trials show combo therapy better prevents brain metastases, improving intracranial response and PFS compared with osimertinib alone.
Matthew Gumbleton, MD
Matthew Gumbleton, MD, is a medical oncologist at Huntsman Cancer Institute, University of Utah.
Articles by Matthew Gumbleton, MD
New trial data weigh EGFR lung cancer first-line combos, hinting amivantamab–lazertinib may edge osimertinib plus chemo, especially with TP53.
Trial data guide EGFR lung cancer first-line choices: amivantamab+lazertinib may edge osimertinib+chemo, especially with TP53 mutations.
Compare EGFR lung cancer first-line options—osimertinib, amivantamab/lazertinib, or chemo combo—balancing visits, survival, and risks.
Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus lazertinib, and osimertinib plus chemotherapy against Mrs. Chen's stated goals of maximizing long-term survival, minimizing clinic visits, and staying chemo-free if possible.
Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with progressive shortness of breath and about 10 pounds of unintentional weight loss over 2 months.